Multiple Sclerosis: Multimedia

References

1. Rodriguez M, Karnes WE, Bartleson JD, et al. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology. Jun 1993;43(6):1100-4. [Medline].

2. Pandey K, Lublin FD. Clinically isolated syndrome and multiple sclerosis: rethinking the arsenal. Curr Treat Options Neurol. May 2009;11(3):193-202. [Medline].

3. Liang J, Zhang H, Hua B, Wang H, Wang J, Han Z, et al. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult Scler. May 2009;15(5):644-6. [Medline].

4. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology. Aug 1998;51(2):529-34. [Medline].

5. Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol. Oct 2007;64(10):1407-15. [Medline].

6. Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?. Neurology. Oct 9 2007;69(15):1498-507. [Medline].

7. Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. Jul 30 1998;339(5):285-91. [Medline].

8. Edlich RF, Hammarskj M. Multiple sclerosis. In: Tintinalli JE, ed. Emergency Medicine [book on CD-ROM]. 4^th ed. 1997:chap 197.

9. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet. Mar 1 1997;349(9052):589-93. [Medline].

10. Francis GS, Evans AC, Arnold DL. Neuroimaging in multiple sclerosis. Neurol Clin. Feb 1995;13(1):147-71. [Medline].

11. [Best Evidence] Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. Oct 10 2006;67(7):1242-9. [Medline].

12. Kelley J, ed. Demyelinating diseases. In: Textbook of Internal Medicine [book on CD-ROM]. 3^rd ed. Lippincott-Raven; 1996:chap 437.

13. Little N. Special neurologic problems: demyelinating disease. In: Rosen P, ed. Emergency Medicine [book on CD-ROM]. 3^rd ed. Mosby; 1992:chap 95.

14. Lublin FD, Whitaker JN, Eidelman BH, et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. Jan 1996;46(1):12-8. [Medline].

15. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. Sep 28 2000;343(13):938-52. [Medline].

16. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. Nov 7 1998;352(9139):1498-504. [Medline].

17. Pryce G, Baker D. Emerging properties of cannabinoid medicines in management of multiple sclerosis. Trends Neurosci. May 2005;28(5):272-6. [Medline].

18. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain. Jun 1997;120 ( Pt 6):1085-96. [Medline].

19. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. Jan 29 1998;338(5):278-85. [Medline].

20. Tullman MJ, Lublin FD. Combination therapy in multiple sclerosis. Curr Neurol Neurosci Rep. May 2005;5(3):245-8. [Medline].

21. Vastag B. Not so fast: research on infectious links to MS questioned. JAMA. Jan 17 2001;285(3):279-81. [Medline].

22. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin. Feb 1995;13(1):119-46. [Medline].

Further Reading

Keywords

multiple sclerosis, MS, central nervous system, CNS, neurologic disorder, idiopathic inflammatory demyelinating disease of the CNS, optic neuritis, transverse myelitis, internuclear ophthalmoplegia, paresthesias, relapse-remitting MS, RR-MS, chronic progressive MS

Contributor Information and Disclosures

Author

Marjorie Lazoff, MD, Editor-in-Chief, Medical Computing Review
Marjorie Lazoff, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Emergency Physicians, American Medical Informatics Association, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Medical Editor

Edmond A Hooker II, MD, DrPH, FAAEM, Assistant Professor, Department of Health Services Administration, Xavier University; Associate Clinical Professor, Department of Emergency Medicine, University of Louisville; Assistant Clinical Professor, Department of Emergency Medicine, Wright State University
Edmond A Hooker II, MD, DrPH, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American Public Health Association, Society for Academic Emergency Medicine, and Southern Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

J Stephen Huff, MD, Associate Professor, Emergency Medicine and Neurology, Department of Emergency Medicine, University of Virginia Health Sciences Center
J Stephen Huff, MD is a member of the following medical societies: American Academy of Emergency Medicine, American Academy of Neurology, American College of Emergency Physicians, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital
Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: WebMD Salary Employment